HANSOH PHARMA(HK:03692) 智通财经网·2025-08-20 01:46Group 1 - The core point of the news is that Hansoh Pharmaceutical (03692) experienced a significant drop in stock price after announcing a placement of 108 million shares at a discount, with proceeds aimed at funding various R&D initiatives [1] - The company reported a revenue of 7.434 billion yuan for the first half of the year, representing a year-on-year growth of 14.3%, and a net profit attributable to shareholders of 3.135 billion yuan, up 15.0% year-on-year [2] - The revenue from innovative drugs and collaborative products reached 6.145 billion yuan, a year-on-year increase of 22.1%, accounting for 82.7% of total revenue, with collaborative income contributing 1.656 billion yuan [2] Group 2 - Approximately 65% of the net proceeds from the share placement will be allocated to the development of new innovative drugs in areas such as oncology and autoimmune diseases [1] - About 25% of the funds will be used for constructing new innovative drug production facilities and upgrading existing R&D laboratories [1] - The company has entered into a licensing agreement for the GLP-1/GIP receptor agonist HS-20094, with an upfront payment of 80 million USD and milestone payments totaling 1.93 billion USD, which is expected to enhance performance in the second half of 2025 [2]